Nanophage Technologies
Auckland, New Zealand· Est.
A New Zealand biotech delivering ultra‑sensitive diagnostic reagents via a proprietary nanorod scaffold.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A New Zealand biotech delivering ultra‑sensitive diagnostic reagents via a proprietary nanorod scaffold.
Technology Platform
A recombinant filamentous phage‑derived nanorod scaffold that can be densely functionalized with fluorophores, antibodies, or other biomolecules to amplify diagnostic assay signals.
Opportunities
Scalable, high‑signal detection reagents can unlock new low‑cost point‑of‑care diagnostics and enable ultra‑sensitive biomarker assays across oncology, infectious disease, and autoimmunity.
Risk Factors
Adoption depends on validation of the nanorod scaffold in regulated diagnostic workflows and on securing manufacturing capacity to meet global demand.
Competitive Landscape
Competes with traditional antibody kits and emerging nanobody/polymer scaffolds; differentiation stems from the biologically derived, genetically programmable nanorod platform that offers superior signal density.